The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements
from Applied Health Economics and Health Policy at http://bit.ly/2bDC2rt on August 31, 2016 at 03:54PM Abstract The high cost of novel treatments is the major driver of negative or restricted reimbursement decisions by healthcare payers in many countries. Costly drugs can be subject to Market Access Agreements (MAAs), which are financial (Commercial Agreements [CAs]) or […]
You must be logged in to post a comment.